Washington: IDRI (Infectious Disease Research Institute) and Medicago Inc. have reported positive interim results from a Phase I clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").The results were announced at the World Vaccine Congress in Washington, DC.The H5N1 vaccine was found to be safe and well-tolerated and induced a solid immune response exceeding the three CHMP (Committee for Medicinal Products for Human Use) immunogenicity criteria for licensure of influenza vaccines.The vaccine was tested in three different configurations: using IDRI`s Glucopyranosyl Lipid A ("GLA") formulated adjuvant, given both intramuscularly and intradermally, and using alum intramuscularly. All three configurations exceeded the CHMP criteria.IDRI is a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease while Medicago Inc. is a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs).
Rahul Gandhi addresses FICCI meet
Is AAP afraid to form a govt?
Adarsh scam: A tale of greed and nepotism?
Lieutenant Governor Najeeb Jung recommends President`s rule in Delhi